Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to -$6.7 million.

  • Usana Health Sciences' Net Income towards Common Stockholders fell 16280.76% to -$6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.6 million, marking a year-over-year decrease of 6769.35%. This contributed to the annual value of $42.1 million for FY2024, which is 3406.28% down from last year.
  • As of Q3 2025, Usana Health Sciences' Net Income towards Common Stockholders stood at -$6.7 million, which was down 16280.76% from $10.4 million recorded in Q2 2025.
  • Usana Health Sciences' Net Income towards Common Stockholders' 5-year high stood at $39.6 million during Q1 2021, with a 5-year trough of -$6.7 million in Q3 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was $17.0 million (2023), whereas its average is $17.7 million.
  • As far as peak fluctuations go, Usana Health Sciences' Net Income towards Common Stockholders surged by 3666.23% in 2021, and later plummeted by 16280.76% in 2025.
  • Over the past 5 years, Usana Health Sciences' Net Income towards Common Stockholders (Quarter) stood at $27.3 million in 2021, then fell by 16.57% to $22.8 million in 2022, then dropped by 26.47% to $16.8 million in 2023, then tumbled by 73.26% to $4.5 million in 2024, then tumbled by 248.57% to -$6.7 million in 2025.
  • Its last three reported values are -$6.7 million in Q3 2025, $10.4 million for Q2 2025, and $9.3 million during Q1 2025.